Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne ...Middle East

--To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled patients are expected to complete 12-week treatment by the end of February 2023 -- Clinical efficacy observed in patients who have completed 12-week treatment of ASC40 or placebo was...

Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne )

Also on site :

• Terrorist plot foiled in Russia’s Kaliningrad – FSB
• Old Navy Is Selling a 'Very Comfortable' Mini Dress for Just $17, and Shoppers Say It’s 'Perfect' for Summer
• EU state accuses Ukraine of spying